| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2004, Vol. 104, No. 12, pp. 3766-3773. Prepublished online as a Blood First Edition Paper on August 10, 2004; DOI 10.1182/blood-2004-02-0578.
PHAGOCYTES A down-regulatable E-selectin ligand is functionally important for PSGL-1independent leukocyteendothelial cell interactionsFrom the Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; and Institut für Zellbiologie, Zentrum für Molekularbiologie der Entzündung (ZMBE), Universität Münster and Max-Planck-Institute, Münster, Germany.
P-selectin glycoprotein-1 (PSGL-1) supports P-selectindependent rolling in vivo and in vitro. However, controversy exists regarding the importance of PSGL-1dependent and independent E-selectin rolling. Using antibodies against PSGL-1 and PSGL-1-/- mice, we demonstrated abolition of P-selectindependent rolling but only partial inhibition of E-selectinmediated rolling in the cremaster microcirculation following local administration of tumor necrosis factor (TNF- ). In vitro studies demonstrated that binding of recombinant mouse E-selectin chimera to PSGL-1-/- neutrophils was dramatically decreased in mice treated systemically but not locally with TNF- . Further, PSGL-1 blockade abolished E-selectindependent rolling in wild-type mice following systemic TNF- administration but not local TNF- administration. Together, these data support an E-selectin ligand present on PSGL-1-/- neutrophils that is down-regulatable upon systemic but not local activation. To determine whether the PSGL-1independent E-selectin ligand was physiologically important, we used a P- and E-selectindependent cutaneous contact hypersensitivity model. Binding studies showed no E-selectin ligand down-regulation in this model. The few cells that rolled on E-selectin ligand following PSGL-1 antibody administration or in PSGL-1 deficiency were sufficient to induce profound contact hypersensitivity. In conclusion, E-selectin mediates PSGL-1dependent and independent rolling and the latter can be down-regulated by systemic activation and can replace PSGL-1 to support the development of inflammation.
Leukocyte accumulation into sites of injury or infection requires a multistep process that involves rolling, adhesion, and emigration. The selectin family of adhesion molecules is responsible for the initial contact of leukocytes with the vascular endothelium. The selectin family consists of 3 closely related cell-surface molecules termed L-selectin, E-selectin, and P-selectin.1 L-selectin is constitutively expressed on leukocytes and binds to ligands on other leukocytes and on activated endothelial cells. E-selectin, expressed on activated endothelial cells, and P-selectin, expressed on activated platelets and endothelial cells, bind to ligands on leukocytes. Recent studies using double- or triple-selectin knockout mice revealed that selectins have overlapping and distinct functions.2,3 Indeed, single-selectin knockout mice revealed only minor deficiencies in leukocyte recruitment in response to tumor necrosis factor (TNF- ) or thioglycollate4,5; more profound deficiencies in double-knockout mice3; and the greatest degree of leukocyte recruitment impairment in E-, L-, and P-selectin triple-knockout mice.2,3,6 Therefore, inhibition of a common ligand for the 3 selectins is a very attractive mode of therapeutic intervention in leukocyte recruitment.
P-selectin glycoprotein ligand-1 (PSGL-1) was first identified in 1992 by Western blotting of membrane extracts of neutrophils and the myeloid cell line HL-60.7 PSGL-1 is a high-affinity ligand for P-selectin and it is preferentially localized to the tips of the microvilli on resting leukocytes.8 In vivo studies have shown that PSGL-1 interaction with P-selectin is required for rolling of human leukocytes or myeloid cells in mesenteric venules of the rat9 as well as in the recruitment of mouse neutrophils into the cremaster muscle.10 However, PSGL-1 is also a ligand for L-selectin11 and for E-selectin.12 Some debate exists over the importance of E-selectinPSGL-1 interactions. An in vivo study demonstrated that microspheres coated with human PSGL-1immunoglobulin G (IgG) chimera attached and rolled on E-selectin in TNF- In this study we systematically examined the importance of PSGL-1dependent and independent rolling using antiPSGL-1 antibodies and PSGL-1-/- mice. We report that PSGL-1 can bind both P-selectin and E-selectin. More importantly, we report an E-selectin ligand distinct from PSGL-1 that is rapidly down-regulated from circulating leukocytes during systemic inflammation making the rolling on P-selectin and E-selectin entirely PSGL-1dependent.
Animals Animals used in this study were male and female C57Bl/6, P-selectin-/-, and PSGL-1-/- mice weighing between 20 and 30 g and older than 8 weeks of age. All mice were on a C57Bl/6 background. C57Bl/6 and P-selectin-/- mice were purchased from The Jackson Laboratories (Bar Harbor, ME) and PSGL-1-/- mice were supplied by Dr Daniel Bullard (University of Alabama) and originally made by Dr B. Furie (Center for Haemostasis and Thrombosis Research, Harvard Medical School, Boston, MA). A minimum of 3 to 6 animals was used in each experimental group. Intravital microscopy Animals were anesthetized by intraperitoneal injection of a mixture of 10 mg/kg xylazine (MTC Pharmaceutical, Cambridge, ON, Canada) and 200 mg/kg ketamine hydrochloride (Rogar/STB, London, ON, Canada). All mice were kept at 36°C to 37°C. The right jugular vein was cannulated to administer anesthetic, fluorescent dyes, and antibodies. Animals were then prepared as follows to view either the skeletal muscle (cremaster) microcirculation or dermal (ear preparation) microcirculation. Cremaster muscle preparation. An incision was made in the scrotal skin to expose the left cremaster muscle, which was then carefully removed from the associated fascia. A lengthwise incision was made on the ventral surface of the cremaster muscle. The testicle and epididymis were separated from the underlying muscle and reintroduced into the abdominal cavity. The muscle was then spread out over an optically clear viewing pedestal and secured along the edges with 3-0 suture. The exposed tissue was superfused with warm bicarbonate-buffered saline (pH 7.4). The cremaster microcirculation was observed through an intravital microscope (Axioskop; Carl Zeiss, Don Mills, ON, Canada) with a x 10 eyepiece and a x 25 objective lens. Single unbranched venules (20-40 µm in diameter) were selected for study and images of the microcirculation were recorded using a video camera (Panasonic-Digital 5100; Panasonic, Secaucus, NJ) and videocassette recorder (VCR). Ear skin preparation. The hair on the left ear was removed using hair removal lotion. The left ear was covered with physiologic saline and gently positioned between a microscope slide and a coverslip on a stage of an intravital microscope as previously described.16 Due to the thickness of the ear, leukocyteendothelial cell interactions were not visible by transillumination. Therefore, for this protocol, animals were injected with the fluorescent dyes fluorescein isothiocyanate (FITC)bovine albumin (10 mg/kg intravenously; Sigma Chemical, St Louis, MO) and rhodamine 6G (0.3 mg/kg intravenously; Sigma Chemical) immediately before microscopic visualization. FITCbovine albumin allowed the visualization of the microvasculature. At the dose used, Rhodamine 6G labels leukocytes and has been shown to allow detection of the same number of rolling leukocytes as transmitted light. It has no effect on leukocyte kinetics per se.17 Rhodamine 6Gassociated fluorescence was visualized by epi-illumination at 510- to 560-nm emission filter.17 The ear microcirculation was observed through the same intravital microscope as described for cremaster muscle preparation but with a x 40 water immersion objective lens. A fluorescent camera (model C-2400-08; Hammamatsu Photonics, Hammamatsu City, Japan) was used to project the images onto a monitor, and the images were recorded for playback analysis using a VCR. Single unbranched venules (20-40 µm in diameter) were selected and, to minimize variability, the same section of the venule was observed throughout the experiment. The number of rolling leukocytes and leukocyte velocity were determined off-line during video playback analysis.
Measurements. For both skin and muscle preparations, rolling leukocytes were defined as leukocytes that rolled at a velocity slower than that of red blood cells. Leukocyte rolling velocity was measured for the first 10 to 20 leukocytes entering the field of view at the time of recording and was determined as the time required for a leukocyte to traverse a 100-µm venule length. Leukocytes were considered adherent to the venular endothelium if they remained stationary for 30 seconds or longer. Red blood cell velocity (VRBC) was measured online using an optical Doppler velocimeter (Microcirculation Research Institute, Texas A&M University, College Station, TX) and was only measured for the skeletal muscle preparation, as determination of VRBC using fluorescence was not possible. Venular blood flow in the skeletal muscle preparation was calculated from the product of cross-sectional area and mean red blood cell velocity (Vmean = VRBC/1.6), assuming cylindrical geometry. Venular wall shear rate (
Experimental protocol. TNF- Oxazolone-induced contact hypersensitivity (CHS). Mice were sensitized for CHS response by topical application of 50 µL of 5% oxazolone (Sigma Chemical) in acetoneolive oil vehicle (4:1) to the shaved flank. One week later, mice received a 10-µL challenge of 1% oxazolone solution on the ventral aspect of the left ear. Just prior to this antigen challenge, blocking antibodies against adhesion molecules (antiE- and antiP-selectin or antiPSGL-1) or saline were administered intraperitoneally. At 2 hours and 24 hours after antigen challenge, ear skin venules were visualized via intravital microscopy as previously described.16 Flow cytometry In all groups of experiments described above, blood was withdrawn by cardiac puncture using heparin (10 U/mL). To detect E-selectin ligands, 100 µL of blood was first incubated for 30 minutes with 2.5 µg of recombinant mouse E-selectin/Fc chimera (R&D Systems). Subsequently, red blood cell lysis was performed with OptiLyse B solution (Immunotech, Marseille, France). Binding of neutrophils to E-selectin chimera was detected by incubation for 30 minutes with goat antihuman IgM conjugated to biotin (1:100 antibody dilution; Sigma Chemical) followed by 30 minutes incubation with streptavidin-phycoerythrin (PE) conjugate (Sav-PE; BD Pharmingen, San Diego, CA; 1:50 antibody dilution). Cells stained with secondary and tertiary antibodies alone were used as negative controls. Neutrophil binding to E-selectin chimera was then analyzed on a FACscan machine using CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA). Neutrophils, lymphocytes, and monocytes were identified using FSC (forward scatter) and SSC (side scatter) profiles, which identify size and granularity, respectively.16 Statistical analysis All data are displayed as mean ± SEM. All data were analyzed using Student t test and a Bonferroni correction was applied where multiple comparisons were necessary. A value of P less than .05 was deemed significant.
TNF- induced leukocyte rolling in cremaster microcirculation is dependent on both endothelial selectins
In Figure 1A, approximately 50 to 60 cells/minute rolled in control C57Bl/6 (first column), whereas approximately 30 cells/minute rolled after 3 to 4 hours of local TNF-
P-selectinindependent rolling in TNF-
In another set of experiments we assessed whether the E-selectin component of leukocyte rolling in TNF-
PSGL-1 antibody also inhibits E-selectinmediated leukocyte rolling in TNF-
A limitation of the P-selectin antibody (Ab) is potentially incomplete P-selectin inhibition. Therefore, we also studied P-selectin-/- mice. In control conditions, P-selectin-/- mice have absolutely no rolling leukocytes.28 As reported previously, following TNF-
TNF-
In this series of experiments we used mice deficient in PSGL-1 after 3 to 4 hours of local TNF-
An E-selectin ligand other than PSGL-1 is down-regulated upon activation
Figure 4A demonstrates that neutrophils from wild-type mice bound E-selectin chimera with great avidity (mean fluorescent intensity [MFI] = 2000). There was an 8-fold reduction of E-selectin binding in PSGL-1-/- mice (MFI = 300); however, some binding remained. This binding was not nonspecific, as it was elevated above control values obtained by staining with the secondary and tertiary antibodies alone (data not shown). Interestingly, the local injection of TNF-
The enhanced E-selectin ligand down-regulation with systemic TNF-
Systemic TNF-
Next, we performed experiments in skin, a vasculature wherein E-selectin is the dominant selectin.31 Figure 6A demonstrates that approximately 8 to 10 cells/minute rolled in the C57Bl/6 mouse ear following 3 to 4 hours of systemic TNF-
PSGL-1independent E-selectin ligand has an important physiologic role in a CHS Since the PSGL-1independent E-selectin ligand only mediates rolling of a few cells, we wished to determine whether the E-selectin ligand is important pathologically. We have previously shown that early leukocyte recruitment (within the first 2 hours of antigen challenge) is entirely dependent on P- and E-selectin,16 an observation confirmed in Figure 7A-B. Further, leukocyte recruitment observed at 24 hours of contact sensitivity is dependent upon this early P- and E-selectindependent leukocyte recruitment.16 In fact, the administration of antiP- and E-selectin antibodies at the time of antigen challenge completely abrogated leukocyte recruitment at 24 hours of CHS (Figure 7C-D) in C57Bl/6 mice. This lack of leukocyte recruitment paralleled a lack of inflammation or edema as assessed by histology and ear thickness measurements, respectively (Table 1). We observed that treatment of C57Bl/6 mice with antiPSGL-1 antibody, 4RA10, greatly attenuated leukocyte rolling and adhesion at 2 hours of CHS (Figure 7A-B). However, this did not translate into an attenuated CHS response at 24 hours; indeed, the inflammatory response was similar to that seen in untreated mice as assessed by intravital microscopy (Figure 7C-D) and ear thickness measurement (Table 1). PSGL-1-/- mice yielded similar results as with the application of 4RA10 in wild-type mice (Figure 7; Table 1). However, when an antiE-selectin antibody was administered at the time of challenge in a PSGL-1-/- mouse, no leukocyte recruitment was seen at either 2 or 24 hours of CHS. Clearly, the small number of cells recruited early in CHS by PSGL-1independent, E-selectinmediated rolling were sufficient to reconstitute a full inflammatory response. Figures 7E and 7F are flow cytometry profiles showing that in this model of CHS there is absolutely no down-regulation of E-selectin ligand in either neutrophils or any other cell type at 2 or 24 hours, respectively.
In the present study we report that PSGL-1 inhibition completely blocks P-selectindependent rolling, and a large amount of E-selectindependent rolling. In fact, more than 98% of all rolling was eliminated using the PSGL-1 strategy. However, our data also reveal that there is a small yet consistent number of rolling cells on E-selectin that appear to be resistant to PSGL-1 inhibition. This particular rolling was sensitive to activation inasmuch as TNF- administered systemically caused down-regulation of the PSGL-1independent E-selectin ligand (as assessed by flow cytometry) and eliminated these few cells from interacting with the microvessels. Finally, our data reveal that this very small amount of PSGL-1independent leukocyte rolling was functionally important. In a localized inflammatory response like CHS, those cells that rolled via E-selectin but not PSGL-1 were entirely sufficient to reconstitute a full dermatitis at 24 hours. Clearly, our data would strongly advocate the tandem use of P-selectin and E-selectin antibodies or E-selectin and PSGL-1 antibodies for therapeutic use in localized models of inflammation but would caution against PSGL-1 inhibition therapy alone.
It appears that upon activation, potentially all of the selectin-dependent rolling ligands are down-regulatable molecules, suggesting that down-regulation may be a universally important mechanism for selectin de-adhesion or some other as yet unknown process. Indeed, L-selectin is rapidly shed following leukocyte activation. PSGL-1 has also been reported to be shed following activation with chemoattractants such as platelet-activating factor (PAF), phorbol myristate acetate (PMA),32 as well as proteases and pharmacologic molecules.33 Our data also showed down-regulation of PSGL-1 in vivo following systemic TNF-
The PSGL-1independent, E-selectindependent rolling has been described before by Yang et al.14 They observed ample rolling of cells following TNF-
Clearly, our data demonstrate that the "other" E-selectin ligand(s) can be an important molecule for leukocyte recruitment. Numerous investigators have spent much time trying to identify E-selectin ligands other than PSGL-1 with limited success. Our data would suggest that PSGL-1 is not the only E-selectin ligand, since PSGL-1-/- mice still had E-selectindependent rolling. Although cutaneous lymphocyte-associated antigen (CLA) is another ligand for E-selectin, PSGL-1 is the major glycoprotein carrier of this carbohydrate modification. Therefore, the PSGL-1-/- mice would also be deficient in CLA. L-selectin fulfills some of the characteristics of our unknown E-selectin ligand inasmuch as L-selectin is shed from leukocytes during activation. Moreover, L-selectin was shown to be an E-selectin ligand in humans.34,36 However, mouse L-selectin has been shown not to bind mouse E-selectin, making this an unlikely ligand in our study.35 E-selectin ligand-1 (ESL-1),37,38 CD66-nonspecific cross-reacting antigen,39 CD43,40 and
Using PSGL-1 antibodies and the PSGL-1-/- mice has helped us to demonstrate that there exists a PSGL-1independent ligand that is easily down-regulated during systemic inflammation but can play a very important role in leukocyte recruitment to local sites of inflammation. The loss of this ligand in models like systemic TNF-
Submitted February 19, 2004; accepted July 25, 2004.
Prepublished online as Blood First Edition Paper, August 10, 2004; DOI 10.1182/blood-2004-02-0578.
Supported by a group grant from the Canadian Institutes of Health Research (CIHR; P.K.). P.K. is a Canada Research Chair and an Alberta Heritage Foundation for Medical Research (AHFMR) scientist. G.A. and C.S.B. are fellows of the Canadian Association for Gastroenterology and J.M.H. is an AHFMR and CIHR training program student. R.C.O.Z. is a Multiple Sclerosis Society fellow.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Paul Kubes, Department of Physiology and Biophysics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada, T2N 4N1; e-mail: pkubes{at}ucalgary.ca.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||